NCT05398913

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Hospital Nacional de Parapléjicos de Toledo · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Detailed description

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test. Main goal is to test safety of Rimonabant in a specific population (incomplete spinal cord injury).

Conditions

• Spinal Cord Injuries

Interventions

Type	Name	Description
DRUG	Rimonabant	Rimonabant

Timeline

• Start date: 2021-05-12
• Primary completion: 2022-06-07
• Completion: 2022-06-07
• First posted: 2022-06-01
• Last updated: 2022-11-15

Locations

1 site across 1 country: Spain